LUNGevity is changing what it means to be diagnosed and live with lung cancer through advocacy, research, and community, every day. 

Increasing Diversity in the Lung Cancer Workforce 

The newly launched LUNGevity Minority Mentorship and Training Program supports diversity and inclusivity within the scientific lung cancer community and offers participants the training they need to thrive in their careers. 

Eugene Manley, Jr, PhD, joined Black Press USA to talk about the importance of diversity and inclusivity in STEM and how this new program helps the next generation of minority lung cancer researchers and clinicians be successful. Listen to the conversation here. 

LUNGevity Award Sparks New Biomarker Research 

Dr. Pitroda’s work – finding a new biomarker for metastatic non-small cell lung cancer (NSCLC) -- is likely to improve outcomes for patients with many types of cancer by helping personalize their treatment plans. 

Transforming ALK-Positive Lung Cancer 

Patient organization ALK Positive, in partnership with LUNGevity, recently awarded $1.75 million to three different research projects to work towards their goal of transforming advanced ALK-positive lung cancer into a chronic or curable disease.  

The selected projects are addressing unanswered questions in the ALK space to quickly improve outcomes for the 5% of NSCLC patients with an ALK-positive gene. 

The Survivor Challenge for LUNGevity HOPE/COPE Summit 2023 is Now Open! 

LUNGevity’s annual HOPE/COPE Summit is a unique three-day event that educates, empowers, and creates a community of support for people affected by lung cancer. The Survivor Challenge is a way for survivors and caregivers to raise money and get free round-trip US transportation and hotel for the May 5-7 HOPE/COPE Summit in Washington, DC.  

If you raise $1,500 by April 1, 2023, you’re eligible for transportation and hotel for one person. If you raise $2,000, you can invite a friend or family member and get transportation for two with a shared hotel room.  

Registration for the HOPE/COPE Summit opens in January. A limited number of travel grants are available for first-time attendees. 

Lung Cancer Screening in Harvard Public Health Magazine 

Upal Basu Roy, PhD, MPH, LUNGevity’s Executive Director of Research, published an opinion piece in Harvard Public Health: Lung cancer kills 130,000 Americans a year, but screening is rare. Dr. Basu Roy shares the reasons why fewer than 6% of Americans at risk for developing lung cancer get screened annually. He calls for health care provider education, expanded eligibility and improved patient access, and awareness that lung cancer is no longer a death sentence, especially when caught early. 

Webinars to Watch Now  

LUNGevity recently hosted a variety of webinars to help people learn about lung cancer and the best ways to navigate the disease.  

• Strategies for Survivorship 
  A wide-ranging conversation that touches on targeted therapies for early-stage and metastatic lung cancer, managing the social, emotional, and physical side effects of cancer treatment, and resources to use on your survivorship journey hosted by Johns Hopkins Kimmel Cancer Center and LUNGevity. 
• Learn with LUNGevity and UChicago Medicine 
  Hear from experts about the latest in lung cancer treatment and ways to navigate your diagnosis. Learn about vital support programs and resources offered by LUNGevity Foundation and UChicago Medicine Comprehensive Cancer Center. 
• Learn with LUNGevity and Sentara Cancer Network 
  Hear from lung cancer experts and learn about resources and support programs offered by LUNGevity Foundation, Virginia Oncology Associates, and Sentara Cancer Network. 
• Metastatic Brain Tumors and Lung Cancer 
  About 25% of lung cancer patients will also develop brain metastases. LUNGevity and the American Brain Tumor Association (ABTA) discuss how metastatic brain tumors affect your lung cancer care. 

Attention All LUNGevity Shoppers 

Best of all, your donation will support lung cancer research, education, and support programs.   

Thank you, and wishing you the best this holiday season! 

Fall Fresh Air Newsletter 

The fall edition of the bi-annual Fresh Air Newsletter is out now! The featured article on The Global Landscape of Lung Cancer Therapy comes from an in-depth LUNGevity study analyzing the current state of global lung cancer drug development. You can read it online here. 

Additional articles in the Fresh Air Newsletter include: 

• Insurance Coverage for Biomarker Testing 
• Standardizing Clinical Trial Eligibility Criteria 
• New Patient Booklet: Liquid Biopsies 
• The Stigma of Lung Cancer 
• And more...